- Home
- HROW vs EOS Comparison
HROW vs EOS Comparison
Compare HROW & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HROW | EOS |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HROW | EOS |
|---|---|---|
| Price | $41.34 | $22.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $68.86 | N/A |
| AVG Volume (30 Days) | ★ 716.4K | 84.1K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $250,042,000.00 | N/A |
| Revenue This Year | $43.92 | N/A |
| Revenue Next Year | $41.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.83 | N/A |
| 52 Week Low | $20.85 | $15.62 |
| 52 Week High | $50.72 | $20.63 |
Technical Indicators
Market Signals| Indicator | HROW | EOS |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 47.53 |
| Support Level | $36.95 | $21.74 |
| Resistance Level | $41.24 | $22.81 |
| Average True Range (ATR) | 2.64 | 0.41 |
| MACD | 0.52 | 0.02 |
| Stochastic Oscillator | 89.48 | 61.93 |
Price Performance
Historical ComparisonAbout HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.